What Does Granuflo Do During Dialysis Treatments
Fresenius Medical Care manufactures Granuflo, which is a drug that helps regulate acidity levels in the body during dialysis treatments. It is an extremely popular medication, and at one time, Fresenius was administering it to more than 100,000 dialysis patients in America. While the reduction of acids in the blood is crucial for survival, this drug has been linked to severe or fatal instances of cardiovascular distress.
The Food and Drug Administration is investigating whether or not Fresenius was irresponsible in how it revealed this information to the public. An internal memo circulated to the company’s clinics in November 2011 outlined this link, and called on physicians to modify patients’ dosages accordingly. This information, however, was not revealed to the public until March 2012. This may constitute mass tort, or a situation in which a party harms many people with an act of wrongdoing or negligence.
Granuflo operates the same way that competing medications do. Its purpose is to introduce bicarbonate into the bloodstream during dialysis. This lowers the acidity of the bodily fluids and tissues. This is a crucial part of the dialysis process, but this substance also contains acetate, which is broken down into bicarbonate by a person’s system. This essentially means that people receiving the treatment were being overloaded with bicarbonate, which resulted in alkalosis, or an elevated pH level in the body. This increases the chance of cardiac arrest, heart attack or cardiopulmonary arrest by as much as six to eight times.
Anyone who has taken this medication and suffered from the above complications should contact a drug injury lawyer for proper representation.